XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

This prospective, multi-center, randomized, double-blind AV-DAPT study cohort is designed to
collect data to support the FDA DAPT initiative. The protocol for AV-DAPT cohort is designed
according to the HCRI-DAPT (NCT00977938) study protocol, Study IDE # G080186.

A total 8040 patients (5034 in initial enrollment phase and additional ~3000 patients in the
second enrollment phase) enrolled in the XIENCE V USA (NCT00676520) had completed Phase I and
were evaluated at 1 year.

These patients were transferred to the following cohorts in Phase II and followed-up for 1-5
years:

The long-term follow-up cohort of phase II (NCT01120379) consisted of 5020 patients from the
first enrollment phase who were not transferred to the HCRI- DAPT study and remained in the
study beyond 1 year.

Patients from the additional 3000 treated with the XIENCE V EECSS who are free from events
(death, MI, repeat coronary revascularization, stroke, ST, or major bleeding - "severe" or
"moderate" by GUSTO classification) in the first year after the index procedure, and are
compliant with DAPT will be identified as prospective patients for the AV-DAPT cohort. A
total of 870 Patients who are considered as part of the AV-DAPT cohort will continue with
Aspirin therapy and will be randomized at 12 months post index procedure to 18 months of
either active treatment with thienopyridines or placebo. Clinical follow-up will occur at 15,
24, 30 and 33 months. These patients will be followed by Abbott Vascular.

The remaining patients from the additional 3000 patients who did not participate in AV-DAPT
cohort will be followed for the first year only. A study completion form will be filled out
and the patients will not be followed beyond their 1 year visit.

The participants enrolled in this study will be followed by Abbott Vascular but their data
will not be independently analyzed; they will only be analyzed as part of the DAPT study
(NCT00977938) which is sufficiently powered for the study outcomes.

Inclusion Criteria:

- Patients who are enrolled into the XIENCE V USA Study Phase I

- The patient agrees to participate in this study by signing the Institutional Review
Board (IRB) approved informed consent form. Alternatively, the patient's legally
authorized representative agrees to the patient's participation in this study and
signs the informed consent form.

Exclusion Criteria:

- The inability to obtain an informed consent is an exclusion criterion.

Patients must meet the following criteria to be eligible for randomization in the study:

- Patient is "12 Month Clear": "12-Month Clear" patients are free from death, MI,
stroke, repeat coronary revascularization, major bleeding - "severe" or "moderate" by
GUSTO classification, and ST 12 months after stent implantation. Staged PCI is allowed
(same stent type as index); repeat PCI and peri-procedural myocardial infarction
occurring with the index procedure or repeat procedure within the first 6 weeks will
not be considered exclusionary events for the definition of "12 Month Clear".

- Patient is "DAPT Compliant": During the open label portion of this study (time 0-12
months), a patient is considered compliant with the thienopyridine therapy for the
purposes of eligibility if they take between 80% and 120% of the prescribed drug in a
given period without an interruption of therapy longer than 14 days. This information
will be ascertained via data collected at the patient interviews at 6 and 12 months
post-procedure. Compliance at both time points is required to be considered "clear".

- Patient completes 1 year visit within ± 30 days window.

Patients will be excluded from randomization if any of the following criteria are met:

- Pregnant women.

- Switched thienopyridine type or dose within 6 months prior to randomization. Note:
Thienopyridine switching during the open label portion of this study is discouraged.

- PCI or cardiac surgery between 6 weeks post index procedure and randomization.

- Planned surgery necessitating discontinuation of antiplatelet therapy within the 21
months following randomization.

- Current medical condition with a life expectancy of less than 3 years.

- Patients on warfarin or similar anticoagulant therapy.